Actemra ® (tocilizumab) – New indication
March 4, 2021 - Genentech announced the FDA approval of Actemra (tocilizumab), for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Download PDF
